The numbers behind the story

March 20, 2017

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Company’s Formulation manufacturing facility at Goa was inspected by USFDA from March 14th 2017 to March 20th 2017. There were few observations made, and these in the opinion of the Company are correctable ones in respect to which the Company will file the necessary response within the stipulated period of 15 working days. The observations do not impact business continuity and the Company’s supplies to the US market.

March 8, 2017

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Unichem Laboratories Limited is pleased to announce that it has received ANDA approval from the United States Food and Drug Administration (USFDA) for Rizatriptan Benzoate ODT 5mg & 10mg and Rizatriptan Benzoate Tablets USP, 5mg & 10mg which are therapeutically equivalent to Maxalt – MLT Tablets 5mg & 10mg and Maxalt Tablets 5mg 10mg of Merck & Company, Inc.

March 6, 2017

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Company’s formulation manufacturing facility at Ghaziabad was inspected by the USFDA from February 24, 2017 to March 3, 2017. The two observations cited are, in the opinion of the Company, correctable ones in respect of which the Company will file the necessary response within the stipulated period of 15 working days. The observations do not impact business continuity and the Company’s supplies to the US market.

July 23, 2016

Notice of Board Meeting

April 21, 2016

Notice of Board Meeting

April 19, 2016

Notice of Board Meeting

March 8, 2017

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Unichem Laboratories Limited is pleased to announce that it has received ANDA approval from the United States Food and Drug Administration (USFDA) for Rizatriptan Benzoate ODT 5mg & 10mg and Rizatriptan Benzoate Tablets USP, 5mg & 10mg which are therapeutically equivalent to Maxalt – MLT Tablets 5mg & 10mg and Maxalt Tablets 5mg 10mg of Merck & Company, Inc.

March 6, 2017

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Company’s formulation manufacturing facility at Ghaziabad was inspected by the USFDA from February 24, 2017 to March 3, 2017. The two observations cited are, in the opinion of the Company, correctable ones in respect of which the Company will file the necessary response within the stipulated period of 15 working days. The observations do not impact business continuity and the Company’s supplies to the US market.

July 23, 2016

Notice of Board Meeting

April 21, 2016

Notice of Board Meeting

April 19, 2016

Notice of Board Meeting

March 8, 2017

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Unichem Laboratories Limited is pleased to announce that it has received ANDA approval from the United States Food and Drug Administration (USFDA) for Rizatriptan Benzoate ODT 5mg & 10mg and Rizatriptan Benzoate Tablets USP, 5mg & 10mg which are therapeutically equivalent to Maxalt – MLT Tablets 5mg & 10mg and Maxalt Tablets 5mg 10mg of Merck & Company, Inc.

March 6, 2017

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Company’s formulation manufacturing facility at Ghaziabad was inspected by the USFDA from February 24, 2017 to March 3, 2017. The two observations cited are, in the opinion of the Company, correctable ones in respect of which the Company will file the necessary response within the stipulated period of 15 working days. The observations do not impact business continuity and the Company’s supplies to the US market.

July 23, 2016

Notice of Board Meeting

April 21, 2016

Notice of Board Meeting

April 19, 2016

Notice of Board Meeting